ClinConnect ClinConnect Logo
Search / Trial NCT05902702

Isotonic Saline for Children With Bronchiolitis

Launched by SLAGELSE HOSPITAL · Jun 13, 2023

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Nebulized Saline Nasal Saline Drops Nasal Saline Irrigation Respiratory Severity Score

ClinConnect Summary

This clinical trial is studying the use of isotonic saline (a saltwater solution) to help treat bronchiolitis in babies aged 0 to 12 months. Bronchiolitis is a common respiratory infection in young children that can cause symptoms like a runny nose, cough, and difficulty breathing. The main goal is to find out if using isotonic saline—either through a nebulizer (a device that turns liquid medicine into a mist) or by nasal irrigation (washing out the nose with saline)—can help shorten the time babies spend in the hospital compared to no treatment at all. Researchers will also look into which viruses are causing bronchiolitis in children in Denmark and whether certain infections respond better to saline treatment.

To be eligible for the study, babies must be between 0 and 12 months old and show symptoms of bronchiolitis, such as a runny nose or wheezing. Parents will need to give their consent for their child to participate. The trial is not yet recruiting participants, but once it starts, families can expect their child to be randomly assigned to one of three groups: one receiving nebulized saline, another getting nasal saline irrigation, or one that will not receive saline treatment. This research aims to better understand how to support infants with bronchiolitis and improve their care.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Children aged 0-12 months, whose parents give informed consent to participate, with symptoms of bronchiolitis including at least one of:
  • Runny nose
  • Dry and persistent cough
  • Labored breathing (tachypnea, retractions, nasal flaring)
  • Grunting
  • Cyanosis or apnea
  • Wheezing or crackles on auscultation
  • O2 saturations below 92 %
  • Difficulties feeding
  • Exclusion Criteria:
  • Children with cystic fibrosis or other serious congenital lung diseases
  • Children in whom treatment with short-acting beta-2 agonist is initiated (as this is delivered in nebulized isotonic saline).

About Slagelse Hospital

Slagelse Hospital is a leading healthcare institution dedicated to providing high-quality medical care and advancing clinical research. As a prominent clinical trial sponsor, the hospital focuses on innovative studies aimed at improving patient outcomes and enhancing treatment methodologies across various medical disciplines. With a commitment to ethical standards and patient safety, Slagelse Hospital collaborates with multidisciplinary teams of healthcare professionals and researchers to explore new therapeutic approaches and contribute to the advancement of medical knowledge. Through its robust clinical trial programs, the hospital strives to address pressing health challenges and foster a culture of scientific inquiry and excellence in patient care.

Locations

Patients applied

0 patients applied

Trial Officials

Ann-Marie M Schoos, MD, PhD

Principal Investigator

Slagelse Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported